Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Sleep and Breathing
Published in: Sleep and Breathing 4/2009

Open Access 01-11-2009 | Original Article

Diurnal variability of C-reactive protein in obstructive sleep apnea

Authors: Paul J. Mills, Loki Natarajan, Roland von Känel, Sonia Ancoli-Israel, Joel E. Dimsdale

Published in: Sleep and Breathing | Issue 4/2009

Login to get access

Abstract

Objective

The objective of this study is to examine the diurnal variability of C-reactive protein (CRP) in obstructive sleep apnea (OSA).

Methods and measurements

Participants included 44 women and men with untreated OSA (mean apnea/hypopnea index = 37.5, SD ± 28) and 23 healthy adults with no OSA. Sleep was monitored with polysomnography in the University of California San Diego General Clinical Research Center. Over a 24-h period, blood was collected every 2 h, and CRP levels were determined.

Results

Adjusting for age, gender, and body mass index, a significant group by time interaction showed that patients with OSA had higher CRP levels during the daytime (8:00 a.m.–8:00 p.m.) versus the nighttime (10:00 p.m. until 6:00 p.m.; p < 0.001). Non-apneics showed no significant change in CRP levels during the 24 h.

Conclusions

The findings indicate that sleep apnea patients have disproportionately elevated CRP levels in the day versus the nighttime, possibly as a result of carryover effects of nighttime arousal into the daytime.
Literature
1.
2.
3.
4.
5.
6.
7.
Teoh H et al (2008) Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 201(2):318–325CrossRefPubMed
8.
Chung S et al (2009) Endothelial dysfunction and inflammatory reactions of elderly and middle-aged men with obstructive sleep apnea syndrome. Sleep Breath 13(1):11–17CrossRefPubMed
9.
Ye J et al (2007) Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Chin Med J (Engl) 120(17):1482–1486
10.
Punjabi NM, Beamer BA (2007) C-reactive protein is associated with sleep disordered breathing independent of adiposity. Sleep 30(1):29–34PubMed
11.
Kapsimalis F et al (2008) Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. Lung 186(4):209–217. doi:10.​1007/​s00408-008-9082-x CrossRefPubMed
12.
Guilleminault C, Kirisoglu C, Ohayon MM (2004) C-reactive protein and sleep-disordered breathing. Sleep 27(8):1507–1511PubMed
13.
Meier-Ewert HK et al (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47(3):426–430PubMed
14.
15.
16.
17.
18.
Roberts WL et al (2001) Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47(3):418–425PubMed
19.
20.
Diggle PJ, Liang K, Zeger S (1996) Analysis of longitudinal data. Clarendon Press, Oxford
21.
Marler MR et al (2006) The sigmoidally transformed cosine curve: a mathematical model for circadian rhythms with symmetric non-sinusoidal shapes. Stat Med 25(22):3893–3904CrossRefPubMed
22.
Markov D, Goldman M (2006) Normal sleep and circadian rhythms: neurobiologic mechanisms underlying sleep and wakefulness. Psychiatr Clin North Am 29(4):841–853 (abstract vii)CrossRefPubMed
23.
Irwin M et al (1999) Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. J Clin Endocrinol Metab 84(6):1979–1985CrossRefPubMed
24.
Coy TV et al (1996) Sleep apnoea and sympathetic nervous system activity: a review. J Sleep Res 5(1):42–50CrossRefPubMed
25.
Ziegler MG et al (2001) Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest 120(3):887–893CrossRefPubMed
26.
Fletcher EC (2003) Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 26(1):15–19PubMed
27.
Dimsdale JE et al (1997) Sympathetic nervous system alterations in sleep apnea. The relative importance of respiratory disturbance, hypoxia, and sleep quality. Chest 111(3):639–642CrossRefPubMed
28.
Peled N et al (1998) Contributions of hypoxia and respiratory disturbance index to sympathetic activation and blood pressure in obstructive sleep apnea syndrome. Am J Hypertens 11(11 Pt 1):1284–1289CrossRefPubMed
29.
Aso Y et al (2006) High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Metabolism 55(8):1014–1021CrossRefPubMed
30.
Wessel J et al (2007) C-reactive protein, an ‘intermediate phenotype’ for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrener. J Hypertens 25(2):329–343CrossRefPubMed
31.
32.
Entzian P et al (1996) Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines. Am J Respir Crit Care Med 153(3):1080–1086PubMed
33.
Vgontzas AN et al (2005) IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12(3):131–140CrossRefPubMed
34.
Tsioufis C et al (2008) Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J Hum Hypertens 22(7):501–508CrossRefPubMed
35.
Abramson JL et al (2006) Relation of C-reactive protein and tumor necrosis factor-alpha to ambulatory blood pressure variability in healthy adults. Am J Cardiol 98(5):649–652CrossRefPubMed
36.
Zamarron C, Garcia Paz V, Riveiro A (2008) Obstructive sleep apnea syndrome is a systemic disease. Current evidence. Eur J Intern Med 19(6):390–398CrossRefPubMed
37.
Merritt SL (2004) Sleep-disordered breathing and the association with cardiovascular risk. Prog Cardiovasc Nurs 19(1):19–27CrossRefPubMed
Metadata
Title
Diurnal variability of C-reactive protein in obstructive sleep apnea
Authors
Paul J. Mills
Loki Natarajan
Roland von Känel
Sonia Ancoli-Israel
Joel E. Dimsdale
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Sleep and Breathing / Issue 4/2009
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-009-0268-0

Other articles of this Issue 4/2009

Sleep and Breathing 4/2009 Go to the issue

Original Article

Pro-atherogenic cytokine profile of patients with suspected obstructive sleep apnea

Original Article

Impact of microarousal associated with increased negative esophageal pressure in sleep-disordered breathing

Original Article

Comparison of hypopnea definitions in lean patients with known obstructive sleep apnea hypopnea syndrome (OSAHS)

Original Article

Sleep duration, wake/sleep symptoms, and academic performance in Hong Kong Secondary School Children

Original Article

Arousal frequency is associated with increased fatigue in obstructive sleep apnea

Case Report

Refractory cluster headache in a patient with bruxism and obstructive sleep apnea: a case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits